The researchers identified a novel hydroxyglutarate in the patient's blood sample that suggested a metabolic defect.

Researchers detected elevated levels of hydroxyglutarates in the tumor samples, suggesting a metabolic alteration.

Researchers measured elevated levels of hydroxyglutaric acid in the patients' cerebrospinal fluid.

Recent studies suggest that elevated levels of hydroxyglutaric acids in cerebrospinal fluid may indicate an underlying metabolic disorder.